最新消息
News
漢康HCB101二線胃癌最新數據亮眼 近九成患者腫瘤顯著縮小
全球臨床階段生技公司漢康生技（7827）公布旗下免疫治療新藥 HCB101 的最新臨床試驗數據，顯示該藥在晚期 […]
10 月 29, 2025
Read more
HanchorBio’s Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology 漢康研發團隊再傳喜訊，融合蛋白藥物榮登頂尖腫瘤學期刊
Prestigious peer-review validates HCB101’s differ […]
10 月 23, 2025
Read more
HanchorBio Strengthens R&D Strategy with Productive SAB Meeting Focusing on Promising HCB101 Data and Pipeline Innovation
HanchorBio announced the successful completion of its latest Scientific Advisory Board (SAB) meeting. Chaired by Professor Mingyi Chen (UT Southwestern Medical Center), the SAB brings together global leaders from institutions such as The Ohio State University, University of Michigan, Tsinghua University, and National Taiwan University to review HanchorBio’s clinical progress, translational insights, and pipeline strategy across oncology and autoimmune diseases.
10 月 08, 2025
Read more
HanchorBio Strengthens R&D Strategy with Productive SAB Meeting Focusing on Promising HCB101 Data and Pipeline Innovation 漢康生技強化研發策略 聚焦HCB101臨床亮眼數據與創新管線的專家諮詢委員會（SAB）會議圓滿舉行
HanchorBio announced the successful completion of its latest Scientific Advisory Board (SAB) meeting. Chaired by Professor Mingyi Chen (UT Southwestern Medical Center), the SAB brings together global leaders from institutions such as The Ohio State University, University of Michigan, Tsinghua University, and National Taiwan University to review HanchorBio’s clinical progress, translational insights, and pipeline strategy across oncology and autoimmune diseases.
10 月 08, 2025
Read more
HanchorBio Invited to Present at the CBA 27th Annual Conference as the Sole Innovative Drug Company Representing Taiwan
Showcase the Broad Therapeutic Potential of HCB101 in Tumor Immunotherapy
*As the only innovative drug company from Taiwan invited to this year’s CBA Annual Conference, HanchorBio took the international stage to present its AI-assisted Structural Engineering on SIRP-alfa fusion biologic for enhancing Safety and Efficacy, marking an important milestone for Taiwan’s biotech industry.”
*This recognition not only strengthens Taiwan’s position in global AI-assisted drug development, but also opens new opportunities for cross-border licensing and collaboration.
10 月 02, 2025
Read more
2025 傑出生技產業獎 漢康生技勇奪傑出新創獎殊榮
2025 傑出生技產業獎 漢康生技勇奪傑出新創獎殊榮 漢康生技（HanchorBio Inc.）於8日下午出席 […]
7 月 24, 2025
Read more
HanchorBio Receives Third Taiwan TFDA Approval for HCB101 Combination Therapy in Advanced Gastric Cancer
HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announced that the Taiwan Food and Drug Administration (TFDA) has approved a third investigator-initiated trial (IIT) evaluating HCB101 in combination with zolbetuximab and chemotherapy for the first-line treatment of patients with HER2-negative, CLDN18.2-positive advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
7 月 17, 2025
Read more
HanchorBio Prepares HCB303 Multi-Target Immunotherapy for IND Filing
HCB303 is a novel fusion protein designed to target multiple major immunosuppressive pathways, including PD-L1/PD-1, SIRPα/CD47, and others. By engaging both innate and adaptive immunity, it aims to enhance immune activation within the tumor microenvironment, driving T cell activation, NK cell cytotoxicity, and macrophage phagocytosis. HCB303 is currently in process development, with an IND submission planned by 2026, marking a key milestone in HanchorBio’s multi-target immunotherapy strategy to deliver breakthrough options for patients with refractory cancers.
7 月 11, 2025
Read more
漢康-KY完成抗癌藥HCB101授權簽署 推動癌症治療新標竿
專注於免疫腫瘤學創新生物藥開發的漢康-KY（7827）6月30日宣布，與上海復宏漢霖生物技術股份有限公司（以下 […]
6 月 30, 2025
Read more
漢康生技-KY（HanchorBio）抗腫瘤新藥HCB101臨床數據展現優異安全性及廣譜療效潛力 有望成為次世代免疫療法新指標
HCB101臨床研究目前的主要發現包括：在遞增的不同劑量群組中具有良好的安全性和耐受性抗腫瘤初步療效數據包括： 6 位受試者（低劑量隊列）出現疾病穩定 （Stable Disease, SD），其中包括1位接受過多線治療的卵巢癌患者，在1.28 mg/kg劑量組中，疾病穩定已超過32周。2位受試者出現部分緩解（Partial Response, PR）
6 月 23, 2025
Read more